| Digg It |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > The One Best Step to Mazimize Your Disaster Plan |
|
Digg It - The One Best Step to Mazimize Your Disaster Plan
There are as many ways to write an after action report as there are hospitals that are now required to perform disaster drills and write after action reports analyzing the performance of the institution According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product following a disaster or a disaster exercise. Since there are 5,756 licensed hospitals in the United States, there are 5,756 different ways that are currently employed to write the after action review. ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in At most institutions, after action reviews are written by a committee between 12 and 18 individuals, managers and supervisors who in addition to their regular duties, have been charged with analyzing the lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. performance of their departments during an adverse event or disaster exercise. When these individuals meet, they review the disaster plan and the performance of each division of the organization seekin here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe g to identify those areas where they enjoyed success. This list of successes will represent what the committee will keep as part of all future plans. The committee will then review performance to deter d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro mine where the plan failed. From this list of failures, they will perform a “root cause analysis” seeking to determine why the failure occurred at each of these critical locations. This list of failure ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc s, along with the list of root causes, will become the list of those items to be changed in the next plan. In the last year, however, a new recommendation for a more effective after action review proces easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi s has come to light. The recommendation does involve spending a small amount of money. The one best technique for maximizing your disaster plan is to buy index cards. During a disaster or a disaster ex nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ercise, every individual involved in the operation of the hospital, regardless of their role or job, receives an index card. On the front of the index card, these employees will write the one thing that and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ they saw that went extremely well during the disaster or disaster drill. On the back of the card, these employees will write the one key failure that they saw during the course of the disaster operation ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi or disaster exercise. Following the disaster or disaster drill, when it is time to perform the after action review the index cards will be collected and taken to the review committee. The hospital now ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a has thousands of eyes that have critiqued hospital operations. When the committee meets, they will perform their usual analysis of those things that went well and those areas of failure. They will stil dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod l perform their usual root cause analysis attempting to identify the reasons for all failures. Then they will turn to the index cards. If the committee is very, very lucky, on the front of the index ca cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin rds, they will find that the employees saw the same successes as the committee identified. The committee now knows, with certainty, what items to keep as part of the disaster plan. In review, those are tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen as where the employees saw the plan fail; they will find that the committee’s list of critical failures matches the observations of those who worked during the disaster or disaster drill. The committee t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel now knows that their analysis is valid. They identified the same failures as the employees. If the committee is very, very, very lucky, there will be one index card that identifies the early critical f ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ailure that started the domino-like cascade that ultimately led to the failure of the hospital’s disaster plan. When the committee fixes this early failure, the hospital’s disaster plan will be that muc y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products h closer to a perfect plan. Unfortunately, there are no absolutely perfect disaster plans. However, a “near perfect” plan can be achieved. The “near perfect” is that disaster plan that continues to fu . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de nction until one second after the last emergency room patient resulting from the disaster is moved from the emergency room gurney into a regular hospital bed. Because, if a plan can last until one secon elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip d after the last emergency room patient resulting from that disaster leaves the emergency room, then the plan has lasted until recovery has begun. Take this one best step and maximize your disaster plan tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Saving Money on Office Cubicles with Smart Designs and Smart Shopping Corporate Identity - The Relation Between Culture and the Company's Product
|